Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2018 1
2021 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Small-cell lung cancer in never-smokers.
Torres-Durán M, Curiel-García MT, Ruano-Ravina A, Provencio M, Parente-Lamelas I, Hernández-Hernández J, Fernández-Villar A, Barros-Dios JM, Pérez-Ríos M. Torres-Durán M, et al. Among authors: curiel garcia mt. ESMO Open. 2021 Apr;6(2):100059. doi: 10.1016/j.esmoop.2021.100059. Epub 2021 Feb 26. ESMO Open. 2021. PMID: 33640828 Free PMC article.
Frequency and characteristics of familial melanoma in Spain: the FAM-GEM-1 Study.
Márquez-Rodas I, Martín González M, Nagore E, Gómez-Fernández C, Avilés-Izquierdo JA, Maldonado-Seral C, Soriano V, Majem-Tarruella M, Palomar V, Maseda R, Martín-Carnicero A, Puertolas T, Godoy E, Cerezuela P, Ochoa de Olza M, Campos B, Perez-Ruiz E, Soria A, Gil-Arnaiz I, Gonzalez-Cao M, Galvez E, Arance A, Belon J, de la Cruz-Merino L, Martín-Algarra S; Spanish Multidisciplinary Group of Melanoma (GEM). Márquez-Rodas I, et al. PLoS One. 2015 Apr 13;10(4):e0124239. doi: 10.1371/journal.pone.0124239. eCollection 2015. PLoS One. 2015. PMID: 25874698 Free PMC article.
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Maio M, Lewis K, Demidov L, Mandalà M, Bondarenko I, Ascierto PA, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Goodman GR, Simmons B, Ye C, Yan Y, Schadendorf D; BRIM8 Investigators. Maio M, et al. Lancet Oncol. 2018 Apr;19(4):510-520. doi: 10.1016/S1470-2045(18)30106-2. Epub 2018 Feb 21. Lancet Oncol. 2018. PMID: 29477665 Clinical Trial.